Table 3.
Response rate of epidermal growth factor receptor tyrosine kinase inhibitors according to mutation type
| CR | PR | SD | PD | p value | |
|---|---|---|---|---|---|
| Total (n = 363) | 1 (0.3) | 265 (73.0) | 72 (19.8) | 25 (6.9) | |
| E19del (n = 175) | 0.785 | ||||
| Afatinib (n = 53) | 0 | 38 (71.7) | 12 (22.6) | 3 (5.7) | |
| Erlotinib (n = 69) | 1 (1.4) | 54 (78.3) | 10 (14.5) | 4 (5.8) | |
| Gefitinib (n = 53) | 0 | 40 (75.5) | 11 (20.8) | 2 (3.8) | |
| L858R (n = 154) | 0.471 | ||||
| Afatinib (n = 38) | 0 | 30 (78.9) | 6 (15.8) | 2 (5.3) | |
| Erlotinib (n = 61) | 0 | 42 (68.9) | 15 (24.6) | 4 (6.6) | |
| Gefitinib (n = 55) | 0 | 45 (81.8) | 9 (16.4) | 1 (1.8) | |
| Uncommon (n = 34) | 0.332 | ||||
| Afatinib (n = 11) | 0 | 6 (54.5) | 3 (27.3) | 2 (18.2) | |
| Erlotinib (n = 9) | 0 | 4 (44.4) | 4 (44.4) | 1 (11..1) | |
| Gefitinib (n = 14) | 0 | 6 (42.9) | 2 (14.3) | 6 (42.9) |
Data are shown as n (%) per each group
CR complete response, PR partial response, SD stable disease, PD progressive disease, E19del exon 19 deletion, L858R L858R point mutation, Uncommon uncommon mutations